Detailed Narrative
Wave-1 Capex Execution Drives Operational Leverage
The company has successfully transitioned from the investment phase to the execution phase of its 'Wave-1' projects. The commissioning of the AHF project and cGMP-4 Phase-1 facility during the quarter has immediately contributed to the 47% YoY revenue growth. This new capacity, combined with manufacturing excellence initiatives, has resulted in a massive 1,047 basis point expansion in 9M EBITDA margins, reaching 32% compared to 21.5% in the prior year.
Specialty Chemicals Reaches Record Highs
The Specialty Chemicals division reported its highest-ever quarterly revenue of ₹354 crores, growing 60% YoY. This performance was driven by a combination of the Nectar project ramp-up (currently at 50% utilization) and scale-up orders for existing molecules. Management expects this segment to maintain a solid run rate, further bolstered by the upcoming MPP debottlenecking at the Dahej facility scheduled for Q3 FY27.
CDMO Momentum and Aspirational Targets
CDMO revenue grew 61% YoY to ₹127 crores, benefiting from the successful validation and commercial supply commencement from the new cGMP-4 facility. The company now maintains a balanced 50-50 split between early-stage and late-stage/commercial molecules. Management expressed high confidence in 'inching closer' to their aspirational $100 million revenue target for this segment as more molecules move toward commercial readouts.
Strategic Pivot to High-Purity Electronic Chemicals
A key theme of the call was the company's strategic move into the semiconductor and electronic value chain. The new AHF capacity is being positioned as a 'mother plant' to produce electronic-grade gases, including BF-3. Management emphasized that while solar applications are part of the journey, the ultimate goal is to capture the high-margin electronic-grade market, supported by India's Semiconductor Mission 2.0.
Financial Discipline and Future Outlook
Despite heavy Capex, Navin Fluorine maintains a pristine balance sheet with a net debt-to-equity ratio of 0.03x. The company has already surpassed its full-year FY25 revenue in just nine months of FY26. With 'Wave-2' projects like the R32 expansion and Chemours project on track for FY27, the company is well-positioned for sustained growth, leading management to raise their long-term annualized EBITDA margin guidance to 30%.